|
Gene: CD63 |
Gene summary for CD63 |
Gene summary. |
Gene information | Species | Human | Gene symbol | CD63 | Gene ID | 967 |
Gene name | CD63 molecule | |
Gene Alias | LAMP-3 | |
Cytomap | 12q13.2 | |
Gene Type | protein-coding | GO ID | GO:0002090 | UniProtAcc | A0A024RB05 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
967 | CD63 | GSM4909281 | Human | Breast | IDC | 3.27e-07 | -2.82e-01 | 0.21 |
967 | CD63 | GSM4909282 | Human | Breast | IDC | 1.32e-17 | -4.74e-01 | -0.0288 |
967 | CD63 | GSM4909285 | Human | Breast | IDC | 3.22e-35 | 4.42e-01 | 0.21 |
967 | CD63 | GSM4909286 | Human | Breast | IDC | 6.80e-22 | -3.85e-01 | 0.1081 |
967 | CD63 | GSM4909287 | Human | Breast | IDC | 4.87e-06 | -3.31e-01 | 0.2057 |
967 | CD63 | GSM4909288 | Human | Breast | IDC | 7.30e-05 | -4.08e-01 | 0.0988 |
967 | CD63 | GSM4909290 | Human | Breast | IDC | 1.63e-03 | -3.02e-01 | 0.2096 |
967 | CD63 | GSM4909294 | Human | Breast | IDC | 6.08e-22 | -2.57e-01 | 0.2022 |
967 | CD63 | GSM4909296 | Human | Breast | IDC | 1.06e-07 | -2.76e-01 | 0.1524 |
967 | CD63 | GSM4909297 | Human | Breast | IDC | 4.21e-24 | -3.64e-01 | 0.1517 |
967 | CD63 | GSM4909298 | Human | Breast | IDC | 1.04e-12 | -3.10e-01 | 0.1551 |
967 | CD63 | GSM4909302 | Human | Breast | IDC | 8.06e-03 | -2.53e-01 | 0.1545 |
967 | CD63 | GSM4909309 | Human | Breast | IDC | 5.56e-05 | 1.64e-02 | 0.0483 |
967 | CD63 | GSM4909311 | Human | Breast | IDC | 3.83e-44 | -6.42e-01 | 0.1534 |
967 | CD63 | GSM4909312 | Human | Breast | IDC | 3.35e-04 | -1.17e-01 | 0.1552 |
967 | CD63 | GSM4909313 | Human | Breast | IDC | 1.83e-03 | -1.16e-01 | 0.0391 |
967 | CD63 | GSM4909315 | Human | Breast | IDC | 1.61e-10 | -3.60e-01 | 0.21 |
967 | CD63 | GSM4909316 | Human | Breast | IDC | 3.80e-06 | -4.28e-01 | 0.21 |
967 | CD63 | GSM4909318 | Human | Breast | IDC | 3.97e-05 | -6.02e-01 | 0.2031 |
967 | CD63 | GSM4909319 | Human | Breast | IDC | 4.09e-56 | -4.22e-01 | 0.1563 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0043112 | Colorectum | AD | receptor metabolic process | 62/3918 | 166/18723 | 8.18e-07 | 2.85e-05 | 62 |
GO:0007160 | Colorectum | AD | cell-matrix adhesion | 75/3918 | 233/18723 | 3.56e-05 | 6.45e-04 | 75 |
GO:0006898 | Colorectum | AD | receptor-mediated endocytosis | 76/3918 | 244/18723 | 1.07e-04 | 1.59e-03 | 76 |
GO:0030100 | Colorectum | AD | regulation of endocytosis | 67/3918 | 211/18723 | 1.42e-04 | 2.01e-03 | 67 |
GO:0045807 | Colorectum | AD | positive regulation of endocytosis | 35/3918 | 100/18723 | 7.78e-04 | 7.78e-03 | 35 |
GO:0048260 | Colorectum | AD | positive regulation of receptor-mediated endocytosis | 20/3918 | 52/18723 | 2.87e-03 | 2.14e-02 | 20 |
GO:0048259 | Colorectum | AD | regulation of receptor-mediated endocytosis | 35/3918 | 110/18723 | 4.85e-03 | 3.27e-02 | 35 |
GO:0031623 | Colorectum | AD | receptor internalization | 35/3918 | 113/18723 | 7.72e-03 | 4.66e-02 | 35 |
GO:00315891 | Colorectum | SER | cell-substrate adhesion | 86/2897 | 363/18723 | 2.36e-05 | 6.64e-04 | 86 |
GO:00071601 | Colorectum | SER | cell-matrix adhesion | 53/2897 | 233/18723 | 2.10e-03 | 2.06e-02 | 53 |
GO:00301001 | Colorectum | SER | regulation of endocytosis | 48/2897 | 211/18723 | 3.29e-03 | 2.82e-02 | 48 |
GO:00431121 | Colorectum | MSS | receptor metabolic process | 57/3467 | 166/18723 | 8.47e-07 | 2.97e-05 | 57 |
GO:00315892 | Colorectum | MSS | cell-substrate adhesion | 104/3467 | 363/18723 | 1.35e-06 | 4.51e-05 | 104 |
GO:00301002 | Colorectum | MSS | regulation of endocytosis | 63/3467 | 211/18723 | 4.05e-05 | 7.66e-04 | 63 |
GO:00068981 | Colorectum | MSS | receptor-mediated endocytosis | 69/3467 | 244/18723 | 1.18e-04 | 1.82e-03 | 69 |
GO:00071602 | Colorectum | MSS | cell-matrix adhesion | 65/3467 | 233/18723 | 2.77e-04 | 3.67e-03 | 65 |
GO:00458071 | Colorectum | MSS | positive regulation of endocytosis | 33/3467 | 100/18723 | 3.73e-04 | 4.72e-03 | 33 |
GO:00482601 | Colorectum | MSS | positive regulation of receptor-mediated endocytosis | 19/3467 | 52/18723 | 1.66e-03 | 1.49e-02 | 19 |
GO:00482591 | Colorectum | MSS | regulation of receptor-mediated endocytosis | 33/3467 | 110/18723 | 2.33e-03 | 1.90e-02 | 33 |
GO:00316231 | Colorectum | MSS | receptor internalization | 32/3467 | 113/18723 | 7.02e-03 | 4.50e-02 | 32 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0520514 | Breast | Precancer | Proteoglycans in cancer | 30/684 | 205/8465 | 1.00e-03 | 7.18e-03 | 5.50e-03 | 30 |
hsa0520515 | Breast | Precancer | Proteoglycans in cancer | 30/684 | 205/8465 | 1.00e-03 | 7.18e-03 | 5.50e-03 | 30 |
hsa0520523 | Breast | IDC | Proteoglycans in cancer | 42/867 | 205/8465 | 7.69e-06 | 9.99e-05 | 7.48e-05 | 42 |
hsa0520533 | Breast | IDC | Proteoglycans in cancer | 42/867 | 205/8465 | 7.69e-06 | 9.99e-05 | 7.48e-05 | 42 |
hsa0520542 | Breast | DCIS | Proteoglycans in cancer | 39/846 | 205/8465 | 5.36e-05 | 5.58e-04 | 4.11e-04 | 39 |
hsa0520552 | Breast | DCIS | Proteoglycans in cancer | 39/846 | 205/8465 | 5.36e-05 | 5.58e-04 | 4.11e-04 | 39 |
hsa0520516 | Cervix | CC | Proteoglycans in cancer | 60/1267 | 205/8465 | 9.13e-08 | 1.18e-06 | 7.00e-07 | 60 |
hsa0520517 | Cervix | CC | Proteoglycans in cancer | 60/1267 | 205/8465 | 9.13e-08 | 1.18e-06 | 7.00e-07 | 60 |
hsa05205 | Colorectum | AD | Proteoglycans in cancer | 70/2092 | 205/8465 | 1.37e-03 | 8.46e-03 | 5.39e-03 | 70 |
hsa052051 | Colorectum | AD | Proteoglycans in cancer | 70/2092 | 205/8465 | 1.37e-03 | 8.46e-03 | 5.39e-03 | 70 |
hsa052052 | Colorectum | SER | Proteoglycans in cancer | 58/1580 | 205/8465 | 4.37e-04 | 3.82e-03 | 2.77e-03 | 58 |
hsa04142 | Colorectum | SER | Lysosome | 38/1580 | 132/8465 | 2.87e-03 | 2.03e-02 | 1.47e-02 | 38 |
hsa052053 | Colorectum | SER | Proteoglycans in cancer | 58/1580 | 205/8465 | 4.37e-04 | 3.82e-03 | 2.77e-03 | 58 |
hsa041421 | Colorectum | SER | Lysosome | 38/1580 | 132/8465 | 2.87e-03 | 2.03e-02 | 1.47e-02 | 38 |
hsa052054 | Colorectum | MSS | Proteoglycans in cancer | 65/1875 | 205/8465 | 8.66e-04 | 5.38e-03 | 3.29e-03 | 65 |
hsa052055 | Colorectum | MSS | Proteoglycans in cancer | 65/1875 | 205/8465 | 8.66e-04 | 5.38e-03 | 3.29e-03 | 65 |
hsa052056 | Colorectum | FAP | Proteoglycans in cancer | 57/1404 | 205/8465 | 3.05e-05 | 3.29e-04 | 2.00e-04 | 57 |
hsa052057 | Colorectum | FAP | Proteoglycans in cancer | 57/1404 | 205/8465 | 3.05e-05 | 3.29e-04 | 2.00e-04 | 57 |
hsa0520518 | Endometrium | AEH | Proteoglycans in cancer | 53/1197 | 205/8465 | 5.43e-06 | 6.53e-05 | 4.78e-05 | 53 |
hsa0520519 | Endometrium | AEH | Proteoglycans in cancer | 53/1197 | 205/8465 | 5.43e-06 | 6.53e-05 | 4.78e-05 | 53 |
Page: 1 2 3 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CD63 | SNV | Missense_Mutation | rs11574657 | c.482N>T | p.Ser161Leu | p.S161L | P08962 | protein_coding | tolerated(0.22) | benign(0.013) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
CD63 | SNV | Missense_Mutation | novel | c.635N>T | p.Gly212Val | p.G212V | P08962 | protein_coding | tolerated(0.3) | benign(0.393) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CD63 | SNV | Missense_Mutation | c.486G>T | p.Lys162Asn | p.K162N | P08962 | protein_coding | tolerated(0.16) | benign(0.007) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
CD63 | SNV | Missense_Mutation | novel | c.468N>C | p.Lys156Asn | p.K156N | P08962 | protein_coding | tolerated(1) | benign(0.001) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CD63 | SNV | Missense_Mutation | c.457N>T | p.Asp153Tyr | p.D153Y | P08962 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
CD63 | SNV | Missense_Mutation | rs11574657 | c.482C>T | p.Ser161Leu | p.S161L | P08962 | protein_coding | tolerated(0.22) | benign(0.013) | TCGA-AA-A02Y-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CD63 | SNV | Missense_Mutation | rs200393279 | c.358N>T | p.Arg120Trp | p.R120W | P08962 | protein_coding | deleterious(0.05) | possibly_damaging(0.773) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
CD63 | SNV | Missense_Mutation | novel | c.467N>C | p.Lys156Thr | p.K156T | P08962 | protein_coding | tolerated(0.56) | benign(0.001) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CD63 | SNV | Missense_Mutation | novel | c.206N>C | p.Phe69Ser | p.F69S | P08962 | protein_coding | deleterious(0.01) | possibly_damaging(0.724) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CD63 | SNV | Missense_Mutation | novel | c.58N>A | p.Ala20Thr | p.A20T | P08962 | protein_coding | tolerated(0.23) | benign(0.014) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
967 | CD63 | CELL SURFACE, DRUGGABLE GENOME, KINASE | NONSTEROIDAL ANTI-INFLAMMATORY DRUGS | 15608437 | ||
967 | CD63 | CELL SURFACE, DRUGGABLE GENOME, KINASE | NSAIDS | 15608437 |
Page: 1 |